207 results about "Hepatitis virus" patented technology

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

The present disclosure relates to siRNA for inhibiting hepatitis B virus and uses thereof. In particular to an oligonucleotide for inhibiting HBV or a pharmaceutically acceptable salt thereof, the oligonucleotide comprises an antisense strand, the antisense strand comprises at least one modified nucleotide, and the nucleotide sequence of the antisense strand comprises a sequence or fragment as shown in any one of SEQ ID NO: 3-35. According to the present invention, the siRNA provides significant inhibition effects for HBsAg, HBV DNA and HBeAg generated by cccDNA and host genome integrated HBV DNA in vivo and in vitro, the drug effect is lasting, and compared with the original sequence, the optimized sequence improves the inhibition effect and the drug effect period, and reduces the off-target toxicity;

The invention relates to the technical field of molecular biology, and discloses a hepatitis E virus rapid detection method and system based on an animal detection technology, and the method comprises the following steps: carrying out nucleic acid extraction on a hepatitis E virus sample to obtain a nucleic acid extraction sample; establishing a PCR system of the nucleic acid extraction sample, and generating uniform microdroplets of the nucleic acid extraction sample and the PCR system; calculating a rupture coefficient of the uniform microdroplet, performing PCR amplification on the uniform microdroplet to obtain an amplified microdroplet, and performing signal detection on the amplified microdroplet by using a preset fluorescent dual-channel to obtain a fluorescent detection signal; generating a two-dimensional scatter diagram of the amplified droplets to determine FAM positive droplets in the amplified droplets; and analyzing the HEV genotype and variation site of the hepatitis E virus sample to establish an HEV strain evolutionary tree and risk-inducing factors of the hepatitis E virus sample, and generating an HEV geographical distribution heat map of the to-be-detected region by combining the HEV strain evolutionary tree and the risk-inducing factors. According to the invention, the accuracy of rapid detection of hepatitis E virus can be improved.

Use of PGLYRP2 gene and a related drug thereof. The present invention relates to the field of biopharmaceuticals, and in particular, to use of the PGLYRP2 gene and the related drug thereof. The present invention aims to solve the problem that existing drugs can only inhibit the replication of hepatitis B virus and cannot eliminate viral cccDNA. The PGLYRP2 gene is used for preparing a drug for treating a hepatitis B virus infection. The PGLYRP2 gene is used for preparing a drug for eliminating hepatitis B virus cccDNA. Also provided is a gene therapy vector for eliminating hepatitis B virus. The gene therapy vector comprises a promoter, an intron, an enhancer, and a PGLYRP2 gene encoding region. The HBV virus inhibition function and the cccDNA-eliminating effect of the PGLYRP2 protein are defined, so that the elimination of HBV in liver cells and a mouse liver can be significantly promoted.

An oligonucleotide, a conjugate, a composition and the use thereof. The oligonucleotide can inhibit the gene expression of a hepatitis B virus, and can efficiently inhibit the generation of HBsAg and total HBV DNAs, and therefore is expected to realize functional healing of hepatitis B.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:which inhibit the cellular entry of hepatitis B virus (HBV) and / or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and / or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and / or HDV infection. The invention also relates to methods of treating an HBV and / or HDV infection in a subject by administering a therapeutically effective amount of a compound of the present invention.

The invention discloses an efficient gene editing system for streptomyces as well as a construction method and application of the efficient gene editing system. The system comprises a TnpB nuclease which can be expressed in streptomyces and a guide RNA, wherein the guide RNA comprises an RNA skeleton, a gene targeting section and a gene sequence of hepatitis delta virus (HDV) ribozyme. Wherein the gene targeting segment is located at the 3'end of the RNA skeleton and is a nucleic acid fragment with the length of 12-40bp after a TAM sequence (5 'TTGAT) on a target gene; the hepatitis D virus (HDV) ribozyme is used for stabilizing the RNA skeleton-gene targeting section structure. According to the streptomyces mini-gene editing tool provided by the invention, in the presence of a homologous repair template, the gene editing efficiency can reach 70-100% in streptomyces, and the gene editing efficiency under the action of the guide RNA after rational design can reach 100%.

The invention belongs to the technical field of medicines, and discloses application of a compound in prevention and treatment of coronavirus infection and / or diseases caused by coronavirus. In particular discloses application of one or more of G96-69, G96-70, G102-35, G110-74, G115-49 and G118-1 in prevention and treatment of coronavirus infection and diseases caused by the coronavirus, improvement of symptoms caused by the coronavirus and in-vitro inhibition of coronavirus replication in a non-treatment destination, and the G96-69, the G96-70, the G102-35, the G110-74, the G115-49 and the G118-1 have relatively good effects in the aspect of resisting the coronavirus. EC50 for inhibiting mouse hepatitis virus MHV is less than 6 [mu] M; the EC 50 of the HCoV-OC43, the EC 50 of the HCoV-229E and the EC 50 of the HCoV-NL63 which are inhibited by the G96-69 and the G96-70 are all smaller than 2 [mu] M.

The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and application, and belongs to the field of medical immunology and infectious pathology. The thymus dependent lymphocyte antigen epitope peptide of the hepatitis B virus antigen is characterized in that the amino acid sequence of the epitope peptide comprises any one or more of the following: SPTVWLSVI; an LPLLPIFFCL (low-performance liquid chromatography- CPTVQASKL, and CPTVQASKL; an LPSDFFPSI (Liquefied Peptide The amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that the immune effect of resisting the hepatitis B virus is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for hepatitis B virus infection, can also be used for preparing detection reagents for detecting hepatitis B virus specific cytotoxic thymus dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of hepatitis B.

The invention relates to the field of biological medicine, and discloses application of bionic high-density lipoprotein nanoparticles in preparation of drugs for targeting hepatitis virus receptor-1. The bionic high-density lipoprotein nanoparticle disclosed by the invention is composed of phospholipid and apolipoprotein mimetic peptide, wherein the apolipoprotein mimetic peptide is ApoA-I mimetic peptide. According to the invention, the bionic high-density lipoprotein nanoparticles can target hepatitis A virus receptor-1 for the first time, and can deliver drugs to cells of high-expression hepatitis A virus receptor-1 to play a therapeutic role. The biomimetic high-density lipoprotein nanoparticles co-loaded with anti-inflammatory and anti-fibrosis drugs can deliver the drugs to damaged renal tubules in a targeted manner especially for damaged renal tubule epithelial cells with selective high expression of KIM-1, so that kidney injuries are effectively relieved, chronic kidney diseases are treated, disease progression is relieved, and a new solution is provided for treatment of the chronic kidney diseases.

2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA, 21) and its phosphoramidate prodrug (FMCAP, 31) have demonstrated potential anti-HBV activity against both adefovir- resistant as well as lamivudine-resistant double (rtL180M / rtM204V) mutant hepatitis B virus (HBV). In addition, in vitro, these molecules have reinstated a significant activity against lamivudine / entecavir triple mutants (L180M+S202G+M204V). This invention is directed to compounds, pharmaceuticals and methods of treating HBV infections, especially including infections caused by resistant and multiple resistant HBV. Pursuant to the present invention, a complete structure-activity relationship (SAR) of 2'-fluoro-6'-methylene-carbocyclic derived nucleos(t)ides has been evaluated and that analysis is presented herein. Pursuant to the present invention, the synthesis and antiviral evaluation of purine and pyrimidine-derived nucleosides have been reported against wild-type and various HBV mutants. Guanosine analog (FMCG, 25) demonstrated an EC50 value of 0.217μM and cytosine analog (FMCC, 41) expressed a potent EC50 value of 0.0025 μM compared to entecavir (EC50 = 0.0029) against wild-type HBV. Additionally, FMCC (41) maintains its antiviral potency against various HBV mutants. Furthermore, chiral pure FMCAP Sp (34) isomer demonstrated an EC50 value of 1.3 nM and was more potent against several HBV mutants than entecavir.

The invention provides an organ transplantation susceptible virus nucleic acid detection primer probe composition and a kit, and belongs to the technical field of biological detection. The primer probe composition comprises an upstream primer, a downstream primer and a fluorescent probe sequence, wherein the upstream primer and the downstream primer are designed for human cytomegalovirus, JC virus, BK polyoma virus, EB virus, human herpes virus type 6, human herpes virus type 8, human parvovirus B19, torque teno virus, new coronavirus and hepatitis E virus respectively; an upstream primer, a downstream primer and a fluorescent probe sequence of an internal standard are designed aiming at a human housekeeping gene RNaseP. The kit can effectively distinguish 10 viruses, ensures high accuracy, specificity and sensitivity, can complete detection in a short time to obtain a result, and can be transported and stored at normal temperature.

The utility model belongs to the technical field of virus detection reagent tube storage equipment, and provides a quantitative reagent kit for hepatitis B virus nucleic acid detection, including a storage box for centrally storing virus reagent tubes, a protection mechanism for improving the protection effect of the device and preventing the reagent tubes from shaking and causing breakage is arranged above the storage box, and a constant temperature mechanism for improving the preservation effect of the reagent tubes is arranged on the outside of the storage box; the utility model can greatly improve the protection safety provided by the virus reagent tubes when they are placed inside the storage box to a certain extent through the protection mechanism, the flip shaft and protection cover plate provided in the protection mechanism not only facilitate the staff to take and put the reagent tubes, but the compression and cooperation of the sliding screw, the clamping plate and the rotator provided in the screw tightening assembly can effectively improve the safety and stability of the reagent tubes placed in the storage box, prevent the reagent tubes from shaking and colliding and causing breakage, and the sponge plate can also prevent damage to the reagent tubes on the basis of improving the compression effect.

A drug conjugate includes a structure shown by the following formula: Z-(linker-[R]m)n. In the formula, Z is a drug compound, R is a sugar, and m and n are independently an integer from 1 to 6. The drug compound Z is a hepatitis virus targeting drug, a hepatitis B virus (HBV) drug, an inhibitor of apoptosis protein (IAP) antagonist, a multidrug resistance (MDR) inhibitor, or analogues, precursors, prodrugs, derivatives thereof.

The present disclosure encompasses a lipid nanoparticle (LNP) comprising a polypeptide comprising a nucleic acid sequence encoding an engineered meganuclease that binds and cleaves a recognition sequence within a Hepatitis B virus (HBV) genome. Further, the disclosure encompasses pharmaceutical compositions comprising the LNPs, and the use of such compositions for inactivating a pol gene of an HBV genome or an HBV genome fragment in a cell and treating HBV infections or diseases associated with HBV infections.

A method for detecting hepatitis B virus comprising a step of bringing a sample into contact with an antibody which binds to a surface antigen protein of hepatitis B virus, and a lectin. The surface antigen protein of hepatitis B virus may be an S protein, and the lectin may be wheat germ agglutinin. The detection method may involve an ELISA measurement and may be used for testing, prophylaxis, or planning treatment of hepatitis B virus, and for screening medicines.

Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and / or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and / or NS5b proteins. In certain embodiments, the subject is a human subject.

The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; interferon-α; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).

This disclosure provides a recombinant hepatitis C virus glycoprotein comprising heterodimers of E1 and E2 glycoproteins having at least 60% homology with SEQ ID No. 1, engineered furin protease cleavage sites, and hydrophilic amino acid linkers, wherein the E1 and E2 glycoproteins partially or completely lack their respective transmembrane domains. This document further provides nucleic acids encoding the recombinant hepatitis C virus glycoprotein, nanoparticle conjugates comprising the recombinant hepatitis C virus glycoprotein, and compositions comprising the recombinant hepatitis C virus glycoprotein, the nucleic acid, or the nanoparticle conjugate. Applications of the recombinant hepatitis C virus glycoprotein or compositions comprising the glycoprotein are also envisioned.

The invention provides preparation of a novel mRNA vaccine and application of the novel mRNA vaccine in a medicine composition for treating hepatitis B virus diseases. Specifically, the invention provides a chronic hepatitis B infection therapeutic mRNA vaccine, which comprises mRNA for coding a large protein (L protein) region of hepatitis B virus surface antigen, and simultaneously comprises two mRNA for respectively coding a middle protein (M protein) region of hepatitis B virus surface antigen and a small protein (S protein) region, or comprises mRNA for coding the small protein (S protein) region. The mRNA therapeutic vaccine provided by the invention can break the immune tolerance state in chronic hepatitis B infection, and has the potential of functionally curing chronic hepatitis B infection clinically.

Provided herein are antisense oligonucleotides and compositions that include the disclosed ASOs. The disclosed ASOs and compositions can be used for treating hepatitis B.

This invention discloses a primer set for amplifying a novel HCV subtype 6xp and a primer set for detecting drug resistance mutations. The primer set for amplifying the novel HCV subtype 6xp includes nested PCR primers for amplifying the full length of the novel HCV subtype 6xp, while the primer set for detecting drug resistance mutations is a set of primers targeting drug resistance mutation sites in the three functional regions of NS3, NS5A, and NS5B. The primer set provided by this invention has high specificity and high amplification efficiency, enabling specific amplification of the entire genome of the novel HCV subtype 6xp and accurate detection of drug resistance mutation sites in the three functional regions. It is suitable for clinical diagnosis, antiviral treatment guidance, epidemiological surveys, and viral evolution research of this subtype, and has significant clinical application value and scientific research significance.

The present application provides a compound of formula (I), or an optical isomer thereof, a pharmaceutically acceptable salt, a solvated form, or a prodrug. The compound may modulate NTCP function for the prevention and / or treatment of HBV / HDV and hepatitis virus-related diseases, bile acid-related cholestasis disorders, metabolic disorders, and / or liver diseases. Additionally, the present application relates to a pharmaceutical composition comprising such a compound and a method for modulating NTCP.

The invention belongs to the technical field of biology, and particularly relates to application of an N-(quinoline-8-yl) quinoline-8-sulfonamide compound to preparation of a medicine for resisting hepatitis B virus. The structure of the compound comprises a salt as shown in (I) or pharmaceutically acceptable salt of the compound. The compound disclosed by the invention has a good inhibition effect on HBV virus replication on the cell level of HBV infection models such as HepG2.2. 15 and Huh7-NTCP, has anti-hepatitis virus activity, provides a good choice for treating viral hepatitis, and also has important significance for developing more ideal medicines for treating hepatitis B. # imgabs0 #

To provide methods and compositions for reducing virus titer and eliminating virus-infected cells from an individual.SOLUTION: Provided is the use of an anti-CD24 antibody in the production of medicament for use in a method for reducing hepatitis virus in an individual, where the method comprises: contacting the individual to a therapeutically effective dose of the anti-CD24 antibody for a period of time sufficient to reduce the amount of hepatitis virus, where the hepatitis virus is one or more of hepatitis B virus (HBV) and hepatitis delta virus (HDV).SELECTED DRAWING: None

The application provides an RT-RAP primer probe set and kit for detecting blood viruses, and belongs to the technical field of molecular biology. The primer probe set comprises a primer probe set for detecting hepatitis B virus, and / or a primer probe set for detecting hepatitis C virus, and / or a primer probe set for detecting human immunodeficiency virus. The application adopts the detection means of RT-RAA and qPCR in sequence, and can simultaneously and rapidly detect hepatitis B virus, hepatitis C virus and human immunodeficiency virus in combination with the specific primer probe set, has higher sensitivity than ordinary qPCR, greatly shortens the reaction time, and has good specificity.

Provided are: a sensitizer for immunochromatography, which is capable of detecting hepatitis virus with high sensitivity; a measurement method using the sensitizer; and the like. A sensitizer for immunochromatography using hepatitis virus as a substance to be measured, which contains a polymer represented by general formula [1] (in formula [1], R1, R2 and R3 are the same or different groups and each represent a hydrogen atom or a methyl group, R4 represents a hydrogen atom, a cation or a 2, 3-dihydroxypropyl group, l, m and n each represent the number of constituent units, and l: m: n is 20-100: 0-80: 0-80.

The invention provides a triple tetravalent inactivated vaccine for preventing and treating duck viral diseases and application of the triple tetravalent inactivated vaccine, and belongs to the technical field of biological vaccines. A water phase of the vaccine is prepared by matching a type 1 duck hepatitis virus antigen solution, a type 3 duck hepatitis virus antigen solution and a duck reovirus antigen solution, and then adding a duck parvovirus VP2 protein solution to obtain a mixed antigen solution with the final concentration of 40 mu g / ml, the virus content in the type 1 duck hepatitis virus antigen solution and the virus content in the type 3 duck hepatitis virus antigen solution are 106.5 ELD50 / 0.2 ml, and the virus content in the duck reovirus antigen solution is 106.5 ELD50 / 0.2 ml. And the virus content of the duck reovirus antigen is 105.5 TCID50 / ml. The four antigen components in the vaccine are free of mutual interference, good in safety and exact in immune effect, the vaccine can achieve the purpose of preventing multiple diseases by one injection, the stress response of the duck immune vaccine is reduced, meanwhile, the four virus diseases are susceptible to small-day-age ducks, and invasion of the four viruses can be prevented at the same time after immunization. The vaccine preparation method is simple and convenient, and the production cost is greatly reduced.

The invention discloses a digital PCR nucleic acid detection kit, and relates to the technical field of in vitro diagnosis detection, the kit comprises primers, probes, a reaction liquid and a quality control liquid, the kit is used for simultaneously detecting hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E virus, the reaction liquid comprises Master Mix and sterile enzyme-free water, and the quality control liquid is used for simultaneously detecting the hepatitis A virus, the hepatitis B virus, the hepatitis C virus, the hepatitis D virus and the hepatitis E virus. The quality control liquid comprises a negative quality control product and a positive quality control product. Through cooperation of sample collection, sample treatment, digital PCR reaction system preparation, digital PCR amplification and result analysis, nucleic acid detection based on the PCR technology shortens the window period by 50-70% through direct detection of virus genetic materials, becomes a key means for early diagnosis, and adopts the technical principle of digital PCR to realize rapid detection of the virus genetic materials. Compared with a traditional fluorescent quantitative PCR and immunological detection method and a qPCR method, the detection sensitivity is improved by 10-100 times, and absolute quantification can be achieved.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.